Astrazeneca (AZN) Equity Ratio (2015 - 2025)

Astrazeneca's Equity Ratio history runs 11 years deep, the most recent figure standing at 0.43 for Q4 2025.

• In Q4 2025, Equity Ratio rose 8.71% year-over-year to 0.43; the TTM figure through Dec 2025 stood at 0.43 (up 8.71% YoY), while the FY2025 annual figure was 0.43, up 8.71% from the prior year.
• Equity Ratio was 0.43 for Q4 2025 at Astrazeneca, up from 0.39 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 377.76 in Q4 2021 to a low of 0.21 in Q2 2021.
• Historically, Equity Ratio has averaged 56.16 across 5 years, with a median of 0.39 in 2023.
• The sharpest annual moves came in 2021 and 2022: Equity Ratio jumped 123544.63% in 2021, then plunged 99.9% in 2022.
• A 5-year view of Equity Ratio shows it stood at 377.76 in 2021, then plunged by 99.9% to 0.38 in 2022, then surged by 32478.7% to 125.13 in 2023, then sank by 99.69% to 0.39 in 2024, then advanced by 8.71% to 0.43 in 2025.
• The last three Equity Ratio figures came in at 0.43 (Q4 2025), 0.39 (Q4 2024), and 0.38 (Q2 2024), per Business Quant data.